Statistical model for prediction of hearing loss in patients receiving cisplatin chemotherapy

JAMA Otolaryngology - Head and Neck Surgery

Volumn 139, Issue 3, 2013, Pages 256-264

  Johnson, Andrew ^a   Tarima, Sergey ^a   Wong, Stuart ^a   Friedland, David R ^a   Runge, Christina L ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ADULT; AGED; ARTICLE; AUDIOMETRY; AUDITORY THRESHOLD; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HEAD AND NECK CANCER; HEARING IMPAIRMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; TERTIARY HEALTH CARE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AUDIOMETRY; CASE-CONTROL STUDIES; CISPLATIN; FEMALE; HEARING LOSS; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 84875829521     PISSN: 21686181     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaoto.2013.1713     Document Type: Article

References (41)

1. Piel IJ, Meyer D, Perlia CP, Wolfe VI. Effects of cis- diamminedichloroplatinum (NSC-119875) on hearing function in man. Cancer Chemother Rep. 1974;58 (6):871-875.
2. Boyer M, Raghavan D, Harris PJ, et al. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol. 1990;8(1):21-26. (Pubitemid 20032442)
3. Osanto S, Bukman A, Van Hoek F, Sterk PJ, De Laat JA, Hermans J. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol. 1992; 10(4):574-579.
4. Stuart NS, Woodroffe CM, Grundy R, Cullen MH. Long-term toxicity of chemotherapy for testicular cancer: the cost of cure. Br J Cancer. 1990;61(3):479-484. (Pubitemid 20106032)
5. Hinojosa R, Riggs LC, Strauss M, Matz GJ. Temporal bone histopathology of cis-platin ototoxicity. Am J Otol. 1995;16(6):731-740.
6. Kohn S, Fradis M, Pratt H, et al. Cisplatin ototoxicity in guinea pigs with special reference to toxic effects in the stria vascularis. Laryngoscope. 1988;98(8, pt 1):865-871.
7. Marco-Algarra J, Basterra J, Marco J. Cis-diaminedichloro platinum ototoxicity: an experimental study. Acta Otolaryngol. 1985;99(3-4):343-347. (Pubitemid 15032538)
8. Tange RA, Vuzevski VD. Changes in the stria vascularis of the guinea pig due to cis-platinum. Arch Otorhinolaryngol. 1984;239(1):41-47. (Pubitemid 14206254)
9. Rybak LP. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg. 2007;15(5):364-369. (Pubitemid 47373985)
10. Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998;77 (8):1355-1362. (Pubitemid 28140629)
11. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004;40(16):2445- 2451. (Pubitemid 39424959)
12. Melamed LB, Selim MA, Schuchman D. Cisplatin ototoxicity in gynecologic cancer patients: a preliminary report. Cancer. 1985;55(1):41-43. (Pubitemid 15198195)
13. Vermorken JB, Kapteijn TS, Hart AA, Pinedo HM. Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol. 1983;19(1):53-58. (Pubitemid 13138716)
14. Chen WC, Jackson A, Budnick AS, et al. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer. 2006;106(4):820-829. (Pubitemid 43238449)
15. Kano H, Kondziolka D, Khan A, Flickinger JC, Lunsford LD. Predictors of hearing preservation after stereotactic radiosurgery for acoustic neuroma. J Neurosurg. 2009;111(4):863-873.
16. Lasak JM, Klish D, Kryzer TC, Hearn C, Gorecki JP, Rine GP. Gamma knife radiosurgery for vestibular schwannoma: early hearing outcomes and evaluation of the cochlear dose. Otol Neurotol. 2008;29(8):1179-1186.
17. Niranjan A, Lunsford LD, Flickinger JC, Maitz A, Kondziolka D. Dose reduction improves hearing preservation rates after intracanalicular acoustic tumor radiosurgery. Neurosurgery. 1999;45(4):753-765. (Pubitemid 29467802)
18. Timmer FC, Hanssens PE, van Haren AE, et al. Gamma knife radiosurgery for vestibular schwannomas: results of hearing preservation in relation to the cochlear radiation dose. Laryngoscope. 2009;119(6):1076-1081.
19. Wackym PA, Runge-Samuelson CL, Nash JJ, et al. Gamma knife surgery of vestibular schwannomas: volumetric dosimetry correlations to hearing loss suggest stria vascularis devascularization as the mechanism of early hearing loss. Otol Neurotol. 2010;31(9):1480-1487.
20. Low WK, Toh ST, Wee J, Fook-Chong SM, Wang DY. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol. 2006;24(12):1904-1909. (Pubitemid 46638990)
21. Durrant JD, Rodgers G, Myers EN, Johnson JT. Hearing loss: risk factor for cis-platin ototoxicity? observations. Am J Otol. 1990;11(5):375-377. (Pubitemid 20320745)
22. Zuur CL, Simis YJ, Lansdaal PE, et al. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis. Int J Radiat Oncol Biol Phys. 2007;68(5):1320-1325. (Pubitemid 47176789)
23. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/ctc.htm. Accessed December 13, 2012.
24. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991;19 (4):295-300.
25. Chang KW, Chinosornvatana N. Practical grading system for evaluating cis-platin ototoxicity in children. J Clin Oncol. 2010;28(10):1788-1795.
26. Chang KW. Clinically accurate assessment and grading of ototoxicity. Laryngoscope. 2011;121(12):2649-2657.
27. American Academy of Otolaryngology-Head and Neck Surgery Foundation Inc, Committee on Hearing and Equilibrium. Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). Otolaryngol Head Neck Surg. 1995;113(3):179-180.
28. Gardner G, Robertson JH. Hearing preservation in unilateral acoustic neuroma surgery. Ann Otol Rhinol Laryngol. 1988;97(1):55-66. (Pubitemid 18067482)
29. Ad Hoc Committee on Audiologic Management of Individuals Receiving Ototoxic and/or Vestibulotoxic Drug Therapy of the American Speech-Language Hearing Association. Guidelines: audiologic management of individuals receiving cochleotoxic drug therapy. http://www.asha.org/policy/GL1994-00003/. Accessed January 7, 2013.
30. Hétu R. The stigma attached to hearing impairment. Scand Audiol Suppl. 1996; 43:12-24. (Pubitemid 26144492)
31. Tye-Murray N, Spry JL, Mauzé E. Professionals with hearing loss: maintaining that competitive edge. Ear Hear. 2009;30(4):475-484.
32. Fleming S, Peppard S, Ratanatharathorn V, et al. Ototoxicity from cis-platinum in patients with stages III and IV previously untreated squamous cell cancer of the head and neck. Am J Clin Oncol. 1985;8(4):302-306. (Pubitemid 16245556)
33. Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH. High dose cis-platinum diamine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer. 1977;39(4):1372-1381. (Pubitemid 8108287)
34. Laurell G, Jungnelius U. High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope. 1990;100(7):724-734. (Pubitemid 20222873)
35. Rademaker-Lakhai JM, Crul M, Zuur L, et al. Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol. 2006;24(6):918-924. (Pubitemid 46638845)
36. Brock P, Bellman S. Ototoxicity of cisplatinum. Br J Cancer. 1991;63(1):159-160.
37. Aguilar-Markulis NV, Beckley S, Priore R, Mettlin C. Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. J Surg Oncol. 1981;16(2):111-123. (Pubitemid 11125717)
38. Truong MT, Winzelberg J, Chang KW. Recovery from cisplatin-induced ototoxicity: a case report and review. Int J Pediatr Otorhinolaryngol. 2007;71(10): 1631-1638. (Pubitemid 47368695)
39. Einarsson EJ, Petersen H, Wiebe T, et al. Long term hearing degeneration after platinum-based chemotherapy in childhood. Int J Audiol. 2010;49(10):765-771.
40. Qureshy K, Blakley B, Alsaleh S, Quddusi T, Berard S. End points for cisplatin ototoxicity. J Otolaryngol Head Neck Surg. 2011;40(Suppl 1):S45-S48.
41. Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004;26(10):649-655. (Pubitemid 39350398)